SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-036542
Filing Date
2020-11-12
Accepted
2020-11-12 16:14:21
Documents
53
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0920_relmadatherapeutics.htm 10-Q 336365
2 CERTIFICATION f10q0920ex31-1_relmadatherap.htm EX-31.1 11881
3 CERTIFICATION f10q0920ex31-2_relmadatherap.htm EX-31.2 11386
4 CERTIFICATION f10q0920ex32-1_relmadatherap.htm EX-32.1 4327
5 CERTIFICATION f10q0920ex32-2_relmadatherap.htm EX-32.2 4111
  Complete submission text file 0001213900-20-036542.txt   2624849

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE rlmd-20200930.xml EX-101.INS 322034
7 XBRL SCHEMA FILE rlmd-20200930.xsd EX-101.SCH 43334
8 XBRL CALCULATION FILE rlmd-20200930_cal.xml EX-101.CAL 26178
9 XBRL DEFINITION FILE rlmd-20200930_def.xml EX-101.DEF 182333
10 XBRL LABEL FILE rlmd-20200930_lab.xml EX-101.LAB 373688
11 XBRL PRESENTATION FILE rlmd-20200930_pre.xml EX-101.PRE 194144
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39082 | Film No.: 201306845
SIC: 2834 Pharmaceutical Preparations